I provide independent and original analysis, pricing metrics and recommendations for the stem, cell, gene and regenerative therapy equities.

Pluristem (PSTI) doing a quick, small and dilutionary overnight offering?

January 18, 2017

  HC Wainright is testing the waters with NO indication of size or amount of shares offered … SELL Pricing closes DOWN -$0.08 and larger volume closes with 372.1 K shares <3 month average =130.37 K shares>  

Histogenics (HSGX) Jumps 40.79% in pre-market

January 12, 2017

  On robust volume in response to its announcement of positive results from NeoCart’s P1 & 2 studies. The results were just published in the online version of the American Journal of Sports Medicine.  

RegMed Investors’ (RMi) mid-day analysis, stocks stumble in minutes

January 11, 2017

  “We’re the largest buyer of drugs in the world, but we don’t bid properly, and we’ll save billions over time and we’ll do that with a lot of other industries,” Trump said. He added that the industry was “getting away with murder.” … Donald Trump, the president-elect.  

Roll Call

The process of calling out our grading of covered companies to rank and review the facts in evidence together with analysis, opinion and objective recommendation.